智通财经网·2025-08-26 12:26Core Insights - Junshi Biosciences (01877) reported a mid-year performance for 2025, with revenue of approximately 1.168 billion RMB, representing a year-on-year growth of 48.64% [1] - The net loss attributable to shareholders was about 413 million RMB, a reduction of approximately 36% compared to the previous year [1] - The basic loss per share was 0.42 RMB [1] Revenue Growth - The revenue increase was primarily driven by the sales of commercialized drugs, with Tuoyi® achieving sales revenue of 954 million RMB in the domestic market, reflecting a year-on-year growth of about 42% [1] Loss Reduction - The reduction in losses was mainly due to the growth in sales revenue of commercialized drugs compared to the same period last year [1] - The company is implementing a "quality improvement and efficiency enhancement" action plan, focusing on more competitive and innovative R&D projects, accelerating clinical development, reducing production costs, and improving sales efficiency to further decrease losses [1]